Trial Profile
A Randomized, Open-label, Single Dose, Two-way Crossover Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet in Healthy Female Volunteers
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 14 Aug 2017
Price :
$35
*
At a glance
- Drugs Ulipristal (Primary)
- Indications Uterine leiomyoma
- Focus Pharmacokinetics
- Sponsors Boryung Pharmaceutical
- 09 Aug 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 May 2017 New trial record